Ameritas Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Ameritas Advisory Services's NBIX Position: Q2 2026 in Review
Ameritas Advisory Services opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 48 shares worth $8.09K. The stake represents ﹤0.01% of the portfolio and ranks #1510 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in NBIX as recently as Q2 2025.
Ameritas Advisory Services first reported a position in NBIX in Q4 2022 and has held it in 4 quarters since. The position peaked at $1.85M in Q4 2022. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Ameritas Advisory Services held 48 shares of Neurocrine Biosciences worth $8.09K as of Q2 2026.
- Neurocrine Biosciences was a new Ameritas Advisory Services position in Q2 2026.
- Neurocrine Biosciences made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1510 holding.
- Ameritas Advisory Services first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 4 quarters since.
- Ameritas Advisory Services's Neurocrine Biosciences position peaked at $1.85M in Q4 2022.
- 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.